3 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow IBI362: new trials by email Literature Review of IBI362 trials Research Report on IBI362
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Placebo, IBI362 - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 181 | 2025-06-20 | 2026-10-20 |
| Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity Tirzepatide, Placebo, IBI362 - Obesity | Phase 1 / Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 98 | 2025-06-17 | 2025-12-15 |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity placebo, IBI362 - Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 141 | 2025-03-26 | 2026-09-22 |
Obesity (2)
Innovent Biologics (Suzhou) Co. Ltd. (3)
China (3)